KRAS and cancer: The absence of effective targeted therapies for LAC (and other cancers) driven by KRAS‐activating mutations places a great emphasis on identifying cooperating factors and/or downstream effectors which mediate the oncogenic activity of mutant KRAS and with the potential to guide the development of indirect strategies to target oncogenic KRAS.